A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects With Advanced Triple-Negative Breast Cancer After Prior Therapy
Sponsor: ImmunityBio, Inc.
Terminated
low enrollment
Other terminated trials from ImmunityBio, Inc.
- Non Small Cell Lung Cancer · Oct 2025
- COVID-19 · Phase PHASE1/PHASE2 · Mar 2024
- Triple Negative Breast Cancer · Phase PHASE1/PHASE2 · Jan 2024
- COVID-19 · Phase PHASE2/PHASE3 · Jul 2023
- Covid19 · Phase PHASE1 · Jan 2023
More terminations from ImmunityBio, Inc.
This PHASE1/PHASE2 trial investigates Advanced Triple Negative Breast Cancer and is currently terminated or withdrawn. ImmunityBio, Inc. leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Apr 2023 — Jul 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Apr 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ImmunityBio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .